SILENCE THER. (SLN)

 

Latest News

Silence Strengthens US Patent Estate

RNS Number: 8200L Silence Therapeutics PLC 24 July 2017 Silence strengthens US patent estate 24 July 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that a further key US patent US 9,695,4...

Presenting at Canaccord Genuity Growth Conference

RNS Number: 8213L Silence Therapeutics PLC 24 July 2017 Silence to present at the Canaccord Genuity 37th Annual Growth Conference 24 July 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, today an...

CEO Ali Mortazavi appointed Chairman of Ultromics

RNS Number: 0579L Silence Therapeutics PLC 14 July 2017 Silence CEO, Ali Mortazavi, appointed Chairman of Ultromics 14 July 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that its CEO...

Silence Therapeutics notes Alnylam statement

Silence Therapeutics has noted Alnylam Pharmaceutical's 7 July press release, which stated that latter company and Sanofi...

All News

DateHeadlineSource
24-07-17Silence Strengthens US Patent EstateRNS
24-07-17Presenting at Canaccord Genuity Growth ConferenceRNS
14-07-17CEO Ali Mortazavi appointed Chairman of UltromicsRNS
10-07-17Silence Therapeutics notes Alnylam statementStockMarketWire
10-07-17IP updateRNS
03-07-17Issue of claim in the UK High CourtsRNS
03-07-17Change of AdviserRNS
29-06-17Holding(s) in CompanyRNS
06-06-17Result of AGMRNS
01-06-17Hiring of Chief Operating OfficerRNS
30-05-17Silence Therapeutics expands intellectual property estateStockMarketWire
30-05-17Silence Continued Expansion of IPRNS
16-05-17Silence Therapeutics expands intellectual property estateStockMarketWire
16-05-17Significant Expansion of Intellectual PropertyRNS
04-05-17Silence Therapeutics schedules AGMStockMarketWire
04-05-17Notice of AGM and Publication of Annual ReportRNS
03-05-17Silence Therapeutics Presents New DataRNS
12-04-17Additional ListingRNS
03-04-17Grant of Share Options to DirectorsRNS
28-03-17Preliminary Results for the year to 31 Dec 2016RNS
08-03-17Notice of ResultsRNS
13-01-17Silence update on stake in Arrowhead PharmaceuticalsStockMarketWire
13-01-17Minority Stake in Arrowhead PharmaceuticalsRNS
09-01-17Silence Therapeutics acquires minority stake in ArrowheadStockMarketWire
09-01-17Acquisition of Minority Stake in ArrowheadRNS
20-12-16Silence Therapeutics notes Quark arbitration resolutionStockMarketWire
20-12-16Silence announces Quark arbitration resolutionRNS
15-11-16CRISPR/Cas9 Gene Editing DataRNS
27-09-16Broker Forecast - Canaccord Genuity issues a broker note on Silence Therapeutics PLCStockMarketWire
27-09-16Silence Therapeutics widens H1 lossStockMarketWire
27-09-16Half-year ReportRNS
22-09-16Notice of ResultsRNS
05-09-16Appointment of CSO and Non-Executive DirectorRNS
18-07-16Director/PDMR ShareholdingRNS
17-06-16Silence resolutions passed at AGMStockMarketWire
17-06-16Result of AGMRNS
01-06-16Holding(s) in CompanyRNS
24-05-16Board Changes, Advisory Board and Notice of AGMRNS
03-05-16Silence Therapeutics Plc to present at the SHARES Investor Evening in London on 19th MayStockMarketWire
19-04-16Director/PDMR ShareholdingRNS

RSS feeds

  • Editorial news feed for LSE:SLN Editorial
  • Regulatory news feed for LSE:SLN Regulatory